Insomnia Therapeutics Market By Treatment Type (Medication {Benzodiazepines, Non-Benzodiazepines, Antidepressants, Antihistamines, Orexin Receptor Antagonists, Melatonin Receptor Agonists}, Therapy {Cognitive Behavioral Therapy for Insomnia (CBT-I), Light Therapy, Relaxation Techniques, Sleep Hygiene Education}), By Route of Administration (Oral, Intravenous, Transdermal, Others), By Formulation (Tablets, Capsules, Liquid Solutions, Patches), By End-User (Hospitals, Clinics, Homecare Settings, Sleep Centers, Research and Academic Institutes), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Table of Contents

1. Methodology & Report Coverage

1.1. Definition & Objective

1.2. Market Evaluation & forecast parameter

1.3. Research Methodology

1.4. Data Validation Sources

1.4.1. Secondary Research

1.4.2. Primary Research

2. Market Overview

3. Insomnia Therapeutics Market: Market Dynamics

3.1. Executive Summary

3.2. Market Driving Factors

3.2.1. Increasing Awareness About Mental Health and Sleep Hygiene

3.2.2. Investment in Research and Development of Innovative Solutions

3.2.3. Expansion of Telehealth and Online Consultation Services for Sleep Disorders

3.3. Key industry pitfalls & challenges

3.3.1. Abundance of Over-the-Counter Sleep Aids as Cheaper Alternatives

3.3.2. Increased Preference for Alternative and Complementary Treatments

3.3.3. Concerns Over Misuse and Abuse of Prescription Sleep Medications

3.4. Market Opportunities

3.4.1. Integration of Artificial Intelligence in Sleep Disorder Management

3.4.2. Expansion of Telemedicine Services for Remote Sleep Therapies

3.4.3. Increased Funding for Research in Sleep Science Innovations

3.5. Porter’s Five Forces Analysis

3.6. PESTLE Analysis

3.7. Regulatory landscape

3.8. Investment Landscape

3.9. ESG Scenario

3.10. Competitive landscape

3.10.1. Company Market Share

3.10.2. Market Positioning

3.10.3. Strategy framework

3.10.4. Recent Acquisitions & Mergers

4. Insomnia Therapeutics Market, Treatment Type Segment Analysis

4.1. Overview Dynamics

4.1.1. Market Revenue Share, By Treatment Type, 2025 & 2035

4.1.2. Key Market Trends, Growth Factors, & Opportunities

4.2. Medication

4.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.2. Benzodiazepines

4.2.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.3. Non-Benzodiazepines

4.2.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.4. Antidepressants

4.2.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.5. Antihistamines

4.2.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.6. Orexin Receptor Antagonists

4.2.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.7. Melatonin Receptor Agonists

4.2.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3. Therapy

4.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3.2. Cognitive Behavioral Therapy for Insomnia (CBT-I)

4.3.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3.3. Light Therapy

4.3.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3.4. Relaxation Techniques

4.3.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3.5. Sleep Hygiene Education

4.3.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

5. Insomnia Therapeutics Market, Route of Administration Segment Analysis

5.1. Overview

5.1.1. Market Revenue Share, By Route of Administration, 2025 & 2035

5.1.2. Key Market Trends, Growth Factors, & Opportunities

5.2. Oral

5.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.3. Intravenous

5.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.4. Transdermal

5.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.5. Others

5.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

6. Insomnia Therapeutics Market, Formulation Segment Analysis

6.1. Overview

6.1.1. Market Revenue Share, By Formulation, 2025 & 2035

6.1.2. Key Market Trends, Growth Factors, & Opportunities

6.2. Tablets

6.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3. Capsules

6.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.4. Liquid Solutions

6.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.5. Patches

6.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

7. Insomnia Therapeutics Market, End-User Segment Analysis

7.1. Overview

7.1.1. Market Revenue Share, By End-User, 2025 & 2035

7.1.2. Key Market Trends, Growth Factors, & Opportunities

7.2. Hospitals

7.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.3. Clinics

7.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.4. Homecare Settings

7.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.5. Sleep Centers

7.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.6. Research and Academic Institutes

7.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

8. Insomnia Therapeutics Market, Region Segment Analysis

8.1. Overview

8.1.1. Global Market Revenue Share, By Region, 2025 & 2035

8.1.2. Global Market Revenue, By Region, 2025-2035(USD Billion)

8.2. North America

8.2.1. North America Market Revenue, By Country, 2025-2035(USD Billion)

8.2.2. North America Market Revenue, By Treatment Type, 2025-2035

8.2.3. North America Market Revenue, By Route of Administration, 2025-2035

8.2.4. North America Market Revenue, By Formulation, 2025-2035

8.2.5. North America Market Revenue, By End-User, 2025-2035

8.2.6. The U.S.

8.2.6.1. U.S. Market Revenue, By Treatment Type, 2025-2035

8.2.6.2. U.S. Market Revenue, By Route of Administration, 2025-2035

8.2.6.3. U.S. Market Revenue, By Formulation, 2025-2035

8.2.6.4. U.S. Market Revenue, By End-User, 2025-2035

8.2.7. Canada

8.2.7.1. Canada Market Revenue, By Treatment Type, 2025-2035

8.2.7.2. Canada Market Revenue, By Route of Administration, 2025-2035

8.2.7.3. Canada Market Revenue, By Formulation, 2025-2035

8.2.7.4. Canada Market Revenue, By End-User, 2025-2035

8.3. Europe

8.3.1. Europe Market Revenue, By Country, 2025-2035(USD Billion)

8.3.2. Europe Market Revenue, By Treatment Type, 2025-2035

8.3.3. Europe Market Revenue, By Route of Administration, 2025-2035

8.3.4. Europe Market Revenue, By Formulation, 2025-2035

8.3.5. Europe Market Revenue, By End-User, 2025-2035

8.3.6. Germany

8.3.6.1. Germany Market Revenue, By Treatment Type, 2025-2035

8.3.6.2. Germany Market Revenue, By Route of Administration, 2025-2035

8.3.6.3. Germany Market Revenue, By Formulation, 2025-2035

8.3.6.4. Germany Market Revenue, By End-User, 2025-2035

8.3.7. France

8.3.7.1. France Market Revenue, By Treatment Type, 2025-2035

8.3.7.2. France Market Revenue, By Route of Administration, 2025-2035

8.3.7.3. France Market Revenue, By Formulation, 2025-2035

8.3.7.4. France Market Revenue, By End-User, 2025-2035

8.3.8. U.K.

8.3.8.1. U.K. Market Revenue, By Treatment Type, 2025-2035

8.3.8.2. U.K. Market Revenue, By Route of Administration, 2025-2035

8.3.8.3. U.K. Market Revenue, By Formulation, 2025-2035

8.3.8.4. U.K. Market Revenue, By End-User, 2025-2035

8.3.9. Italy

8.3.9.1. Italy Market Revenue, By Treatment Type, 2025-2035

8.3.9.2. Italy Market Revenue, By Route of Administration, 2025-2035

8.3.9.3. Italy Market Revenue, By Formulation, 2025-2035

8.3.9.4. Italy Market Revenue, By End-User, 2025-2035

8.3.10. Spain

8.3.10.1. Spain Market Revenue, By Treatment Type, 2025-2035

8.3.10.2. Spain Market Revenue, By Route of Administration, 2025-2035

8.3.10.3. Spain Market Revenue, By Formulation, 2025-2035

8.3.10.4. Spain Market Revenue, By End-User, 2025-2035

8.3.11. Rest of Europe

8.3.11.1. Rest of Europe Market Revenue, By Treatment Type, 2025-2035

8.3.11.2. Rest of Europe Market Revenue, By Route of Administration, 2025-2035

8.3.11.3. Rest of Europe Market Revenue, By Formulation, 2025-2035

8.3.11.4. Rest of Europe Market Revenue, By End-User, 2025-2035

8.4. Asia Pacific

8.4.1. Asia Pacific Market Revenue, By Country, 2025-2035(USD Billion)

8.4.2. Asia Pacific Market Revenue, By Treatment Type, 2025-2035

8.4.3. Asia Pacific Market Revenue, By Route of Administration, 2025-2035

8.4.4. Asia Pacific Market Revenue, By Formulation, 2025-2035

8.4.5. Asia Pacific Market Revenue, By End-User, 2025-2035

8.4.6. China

8.4.6.1. China Market Revenue, By Treatment Type, 2025-2035

8.4.6.2. China Market Revenue, By Route of Administration, 2025-2035

8.4.6.3. China Market Revenue, By Formulation, 2025-2035

8.4.6.4. China Market Revenue, By End-User, 2025-2035

8.4.7. Japan

8.4.7.1. Japan Market Revenue, By Treatment Type, 2025-2035

8.4.7.2. Japan Market Revenue, By Route of Administration, 2025-2035

8.4.7.3. Japan Market Revenue, By Formulation, 2025-2035

8.4.7.4. Japan Market Revenue, By End-User, 2025-2035

8.4.8. India

8.4.8.1. India Market Revenue, By Treatment Type, 2025-2035

8.4.8.2. India Market Revenue, By Route of Administration, 2025-2035

8.4.8.3. India Market Revenue, By Formulation, 2025-2035

8.4.8.4. India Market Revenue, By End-User, 2025-2035

8.4.9. Australia

8.4.9.1. Australia Market Revenue, By Treatment Type, 2025-2035

8.4.9.2. Australia Market Revenue, By Route of Administration, 2025-2035

8.4.9.3. Australia Market Revenue, By Formulation, 2025-2035

8.4.9.4. Australia Market Revenue, By End-User, 2025-2035

8.4.10. South Korea

8.4.10.1. South Korea Market Revenue, By Treatment Type, 2025-2035

8.4.10.2. South Korea Market Revenue, By Route of Administration, 2025-2035

8.4.10.3. South Korea Market Revenue, By Formulation, 2025-2035

8.4.10.4. South Korea Market Revenue, By End-User, 2025-2035

8.4.11. Singapore

8.4.11.1. Singapore Market Revenue, By Treatment Type, 2025-2035

8.4.11.2. Singapore Market Revenue, By Route of Administration, 2025-2035

8.4.11.3. Singapore Market Revenue, By Formulation, 2025-2035

8.4.11.4. Singapore Market Revenue, By End-User, 2025-2035

8.4.12. Rest of Asia Pacific

8.4.12.1. Rest of Asia Pacific Market Revenue, By Treatment Type, 2025-2035

8.4.12.2. Rest of Asia Pacific Market Revenue, By Route of Administration, 2025-2035

8.4.12.3. Rest of Asia Pacific Market Revenue, By Formulation, 2025-2035

8.4.12.4. Rest of Asia Pacific Market Revenue, By End-User, 2025-2035

8.5. Latin America

8.5.1. Latin America Market Revenue, By Country, 2025-2035(USD Billion)

8.5.2. Latin America Market Revenue, By Treatment Type, 2025-2035

8.5.3. Latin America Market Revenue, By Route of Administration, 2025-2035

8.5.4. Latin America Market Revenue, By Formulation, 2025-2035

8.5.5. Latin America Market Revenue, By End-User, 2025-2035

8.5.6. Brazil

8.5.6.1. Brazil Market Revenue, By Treatment Type, 2025-2035

8.5.6.2. Brazil Market Revenue, By Route of Administration, 2025-2035

8.5.6.3. Brazil Market Revenue, By Formulation, 2025-2035

8.5.6.4. Brazil Market Revenue, By End-User, 2025-2035

8.5.7. Argentina

8.5.7.1. Argentina Market Revenue, By Treatment Type, 2025-2035

8.5.7.2. Argentina Market Revenue, By Route of Administration, 2025-2035

8.5.7.3. Argentina Market Revenue, By Formulation, 2025-2035

8.5.7.4. Argentina Market Revenue, By End-User, 2025-2035

8.5.8. Mexico

8.5.8.1. Mexico Market Revenue, By Treatment Type, 2025-2035

8.5.8.2. Mexico Market Revenue, By Route of Administration, 2025-2035

8.5.8.3. Mexico Market Revenue, By Formulation, 2025-2035

8.5.8.4. Mexico Market Revenue, By End-User, 2025-2035

8.5.9. Rest of Latin America

8.5.9.1. Rest of Latin America Market Revenue, By Treatment Type, 2025-2035

8.5.9.2. Rest of Latin America Market Revenue, By Route of Administration, 2025-2035

8.5.9.3. Rest of Latin America Market Revenue, By Formulation, 2025-2035

8.5.9.4. Rest of Latin America Market Revenue, By End-User, 2025-2035

8.6. MEA

8.6.1. MEA Market Revenue, By Country, 2025-2035(USD Billion)

8.6.2. MEA Market Revenue, By Treatment Type, 2025-2035

8.6.3. MEA Market Revenue, By Route of Administration, 2025-2035

8.6.4. MEA Market Revenue, By Formulation, 2025-2035

8.6.5. MEA Market Revenue, By End-User, 2025-2035

8.6.6. GCC Countries

8.6.6.1. GCC Countries Market Revenue, By Treatment Type, 2025-2035

8.6.6.2. GCC Countries Market Revenue, By Route of Administration, 2025-2035

8.6.6.3. GCC Countries Market Revenue, By Formulation, 2025-2035

8.6.6.4. GCC Countries Market Revenue, By End-User, 2025-2035

8.6.7. South Africa

8.6.7.1. South Africa Market Revenue, By Treatment Type, 2025-2035

8.6.7.2. South Africa Market Revenue, By Route of Administration, 2025-2035

8.6.7.3. South Africa Market Revenue, By Formulation, 2025-2035

8.6.7.4. South Africa Market Revenue, By End-User, 2025-2035

8.6.8. Rest of Middle-East & Africa

8.6.8.1. Rest of Middle-East & Africa Market Revenue, By Treatment Type, 2025-2035

8.6.8.2. Rest of Middle-East & Africa Market Revenue, By Route of Administration, 2025-2035

8.6.8.3. Rest of Middle-East & Africa Market Revenue, By Formulation, 2025-2035

8.6.8.4. Rest of Middle-East & Africa Market Revenue, By End-User, 2025-2035

9. Company Profile

9.1. Purdue Pharma L.P.

9.1.1. Business Overview

9.1.2. Financial Performance

9.1.3. Treatment/Service Offerings

9.1.4. Strategies & recent developments

9.1.5. SWOT Analysis

9.2. Takeda Pharmaceutical Company Limited

9.2.1. Business Overview

9.2.2. Financial Performance

9.2.3. Treatment/Service Offerings

9.2.4. Strategies & recent developments

9.2.5. SWOT Analysis

9.3. Merck & Co., Inc.

9.3.1. Business Overview

9.3.2. Financial Performance

9.3.3. Treatment/Service Offerings

9.3.4. Strategies & recent developments

9.3.5. SWOT Analysis

9.4. Eisai Co., Ltd.

9.4.1. Business Overview

9.4.2. Financial Performance

9.4.3. Treatment/Service Offerings

9.4.4. Strategies & recent developments

9.4.5. SWOT Analysis

9.5. Pfizer Inc.

9.5.1. Business Overview

9.5.2. Financial Performance

9.5.3. Treatment/Service Offerings

9.5.4. Strategies & recent developments

9.5.5. SWOT Analysis

9.6. Sanofi S.A.

9.6.1. Business Overview

9.6.2. Financial Performance

9.6.3. Treatment/Service Offerings

9.6.4. Strategies & recent developments

9.6.5. SWOT Analysis

9.7. Johnson & Johnson

9.7.1. Business Overview

9.7.2. Financial Performance

9.7.3. Treatment/Service Offerings

9.7.4. Strategies & recent developments

9.7.5. SWOT Analysis

9.8. Vanda Pharmaceuticals Inc.

9.8.1. Business Overview

9.8.2. Financial Performance

9.8.3. Treatment/Service Offerings

9.8.4. Strategies & recent developments

9.8.5. SWOT Analysis

9.9. Minerva Neurosciences, Inc.

9.9.1. Business Overview

9.9.2. Financial Performance

9.9.3. Treatment/Service Offerings

9.9.4. Strategies & recent developments

9.9.5. SWOT Analysis

9.10. Idorsia Pharmaceuticals Ltd.

9.10.1. Business Overview

9.10.2. Financial Performance

9.10.3. Treatment/Service Offerings

9.10.4. Strategies & recent developments

9.10.5. SWOT Analysis

9.11. Sumitomo Pharma Co., Ltd.

9.11.1. Business Overview

9.11.2. Financial Performance

9.11.3. Treatment/Service Offerings

9.11.4. Strategies & recent developments

9.11.5. SWOT Analysis

9.12. Neurocrine Biosciences, Inc.

9.12.1. Business Overview

9.12.2. Financial Performance

9.12.3. Treatment/Service Offerings

9.12.4. Strategies & recent developments

9.12.5. SWOT Analysis

9.13. Medice Arzneimittel Pütter GmbH & Co. KG

9.13.1. Business Overview

9.13.2. Financial Performance

9.13.3. Treatment/Service Offerings

9.13.4. Strategies & recent developments

9.13.5. SWOT Analysis

9.14. Astellas Pharma Inc.

9.14.1. Business Overview

9.14.2. Financial Performance

9.14.3. Treatment/Service Offerings

9.14.4. Strategies & recent developments

9.14.5. SWOT Analysis

9.15. Harmony Biosciences

9.15.1. Business Overview

9.15.2. Financial Performance

9.15.3. Treatment/Service Offerings

9.15.4. Strategies & recent developments

9.15.5. SWOT Analysis

9.16. Zydus Cadila

9.16.1. Business Overview

9.16.2. Financial Performance

9.16.3. Treatment/Service Offerings

9.16.4. Strategies & recent developments

9.16.5. SWOT Analysis

9.17. Boehringer Ingelheim GmbH

9.17.1. Business Overview

9.17.2. Financial Performance

9.17.3. Treatment/Service Offerings

9.17.4. Strategies & recent developments

9.17.5. SWOT Analysis

9.18. Theravance Biopharma, Inc.

9.18.1. Business Overview

9.18.2. Financial Performance

9.18.3. Treatment/Service Offerings

9.18.4. Strategies & recent developments

9.18.5. SWOT Analysis